Biosimilars Dodge Bullet As High Court Upholds ACA
One of the law’s most relevant provisions for pharmaceutical firms created an approval pathway for biosimilars, the generic equivalents of high-priced brand-name biologics. Many manufacturers had anxiously awaited the high court’s ruling, fearing it could erase that authorization and set the industry back months or years.
“This is a huge victory for...
To view the full article, register now.